Skip to content

Clinical effect of modified decoction of Fangji Huangqi Tang on treatment of polymyalgia rheumatica with dampness obstruction of spleen deficiency

Clinical effect of modified decoction of Fangji Huangqi Tang on treatment of polymyalgia rheumatica with dampness obstruction of spleen deficiency

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100048975
Enrollment
Unknown
Registered
2021-07-19
Start date
2021-08-01
Completion date
Unknown
Last updated
2022-03-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

polymyalgia rheumatica

Interventions

Sponsors

Beijing Hospital of Traditional Chinese Medicine, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Western medicine diagnostic criteria: (1) Aged > 50 years; (2) Muscle pain and morning stiffness in one of the neck, shoulder girdle and pelvic girdle, and the duration of the disease is more than 1 week; (3) ESR increases rapidly and CRP increases; (4) Low-dose glucocorticoids (prednisone<=15mg/day) are effective; (5) No muscle weakness or muscle atrophy, and muscle redness, heat and swelling; (6) Exclude other lesions similar to PMR manifestations such as myositis, tumor, rheumatoid arthritis, chronic infection, etc. 2. Diagnostic criteria for spleen deficiency and damp resistance syndrome: Shenpi fatigue, shortness of breath, lazy speech, low voice, numbness and heavy limbs, heavy muscles and ligaments, soreness and pain, soreness and weakness of limbs, inability to lift, pale complexion, poor appetite, fullness and fullness in the stomach and abdomen, loose stools, the tongue is pale, the body is fat with tooth marks, the coating is white and greasy, and the pulse is deep and slow.

Exclusion criteria

Exclusion criteria: 1. Incomplete data and or non-prescribed medication, etc., which affect the judgment of efficacy or safety; 2. Patients with liver cirrhosis, chronic lung inflammation, patients with peptic ulcer in the past 3 months, recent fractures, etc. who cannot take hormones; 3. Patients taking steroids or immunosuppressants; 4. Obvious abnormal liver and kidney function; 5. Patients with mental illness or disturbance of consciousness who cannot cooperate with treatment.

Design outcomes

Primary

MeasureTime frame
ESR;C-reactive protein;Polymyalgia rheumatica activity score;Evaluation standard of curative effect of traditional Chinese Medicine;

Countries

China

Contacts

Public ContactDong Hongsheng

Beijing Hospital of Traditional Chinese Medicine, Capital Medical University

donghongsheng123@163.com+86 13911226267

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026